drugset / Trial / NCT00703690

MK0767 in Metabolic Syndrome-Dyslipidemia (0767-016)

NCT00703690

Phase 2 Terminated 436 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a clinical trial in patients with Metabolic Syndrome and Dyslipidemia to study the effects of MK0767 on triglycerides.

Timeline

Start
2002-01
Primary completion
2003-12
Completion
2003-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Fenofibrate Small molecule 200 mg
Subject MK0767 Small molecule 2.5 mg
Subject MK0767 Small molecule 5 mg
Subject MK0767 Small molecule 10 mg

Indications